Join Richmond Pharamcology at the 2nd DIA Cardiac Safety Workshop in Japan for our latest TQT Analysis in Japanese and Caucasian Volunteers

Posted:
16
August 2011

Richmond Pharmacology Ltd is proud to announce its participation in the �2nd DIA Cardiac Safety Workshop in Japan,� being held September 5-6, 2011 at Tower Hall Funabori in Tokyo, Japan. The meeting will address the key scientific, clinical and regulatory issues of implementation of ICH-E14 in Japan and bring together experts from multiple disciplines; intended to facilitate an open and productive dialogue between regulatory, industry and academic delegates.As a feature, the first ever formal Japanese Caucasian bridging TQT analysis will be presented by Dr Jorg Taubel, CEO and Principal Investigator of Richmond Pharmacology Ltd. The analysis was carried out jointly between the Department of Pharmacology of Toho University, the Cardiovascular Sciences Research Centre at St Georges University of London and Richmond Pharmacology Ltd. This groundbreaking presentation being held on Day 1, Session 3 from 17h00 to 17h30 promises to be an informative and insightful discussion relating to the recent implementation of ICH-E14.Having successfully completed in excess of 50 studies in Japanese subjects since 2002, many of which have already been used in regulatory submissions in Japan, Richmond Pharmacology Ltd is well positioned to conduct TQT Studies in Japanese subjects outside of Japan and for the conduct of TQT Bridging Studies in a mixed Japanese and Caucasian study populations. To learn more about our specialist expertise in Japanese Studies come meet our team at booth numbers 8-9, where Richmond Pharmacology Ltd will be happy to discuss our capabilities in more detail.If you are interested in attending the 2nd DIA Cardiac Safety Workshop in Japan, click here to register or contact a member of our business development team to arrange a meeting in person. We look forward to seeing you in Tokyo!

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more